clinical trial

December 1, 2017December 1, 2017

Eureka Technologies Receives FDA’s OK to Move T-cell Therapy into Clinical Trials

News

The U.S. Food and Drug Administration (FDA) has approved the T-cell therapy ET190L1-ARTEMIS to move into clinical trials for the treatment of relapsed and refractory CD19-positive non-Hodgkin’s lymphoma (NHL). Following the ... Read more

October 10, 2017

Gazyva Reduces Risk of Disease Progression in Follicular Lymphoma Patients, Clinical Trial Finds

News

Interim analysis of the GALLIUM (NCT01332968) clinical trial shows that treatment with Gazyva plus chemotherapy improves progression-free survival in patients with advanced, CD20-positive, untreated follicular lymphoma. The GALLIUM trial set ... Read more

July 10, 2017July 10, 2017

Potential Oral Therapy for Indolent Non-Hodgkin’s Lymphoma, Duvelisib, Shows Efficacy in Phase 2 Trial

News

An investigative oral therapy, duvelisib, was effective in treating indolent non-Hodgkin’s lymphoma among patients who did not respond to Rituxan (rituximab) and chemotherapy or radioimmunotherapy, according to results from a Phase ... Read more

July 7, 2017July 7, 2017

Response to Kite’s CAR T-Cell Therapy in NHL Isn’t Dependent on Disease Factors, Researchers Say

News

The ZUMA-1 Phase 2 clinical trial of the CAR T-cell therapy axicabtagene ciloleucel (KTE-C19) showed that 82% of patients with treatment-resistant or relapsed aggressive non-Hodgkin’s lymphoma (NHL) responded to the ... Read more

June 12, 2017June 12, 2017

Imbruvica Seen to Improve Long-Term Survival in Certain Leukemia Patients, Trial Data Show

News

People with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia (CLL/SLL) who were treated with Imbruvica (ibrutinib) in a clinical trial — and then followed for several years — ... Read more

April 17, 2017April 17, 2017

Remetinostat Gel Twice a Day Leads to 40% Skin Lymphoma Response Rate, Study Shows

News

Remetinostat gel applied twice a day led to partial or complete responses in 40 percent of patients with skin lymphoma, according to a Phase 2 clinical trial. The trial of ... Read more

March 14, 2017

FDA Gives Orphan Drug Status to eFT508 for Treating Diffuse Large B-cell Lymphoma

News

The U.S. Food and Drug Administration (FDA) has granted orphan drug status to eFT508, which treats diffuse large B-cell lymphoma (DLBCL) by inhibiting proteins associated with the disease. The designation is ... Read more

March 7, 2017March 7, 2017

UNC Lineberger Cancer Center Launches Lymphoma Trials with CAR T-cells

News

The University of North Carolina Lineberger Comprehensive Cancer Center has launched two clinical trials exploring CAR T-cells in patients with lymphoma, making it easier for patients in the Southeast to participate in ... Read more

March 1, 2017

Letermovir Helps Prevent Post-transplant Viral Infections, Clinical Trial Shows

News

Lymphoma patients who obtain stem cell transplants may soon have a new therapy to ward off cytomegalovirus (CMV) infections, the results of a Phase 3 clinical trial indicate. In contrast ... Read more

February 20, 2017October 26, 2017

Denovo Plans Phase 3 Trial of Its DB102 Therapy for Subset of Lymphoma Patients

News

Denovo Biopharma will start a global Phase 3 trial this year to assess its PKCβ inhibitor, DB102, as a first-line therapy for a subset of patients with diffuse large B-cell lymphoma ... Read more